The deal is a dramatic bet that the London-based drug giant can see opportunities connected to the genetics of cancer drugs better than the stock market. It fits into a framework outlined in July by Hal Barron, the widely respected pharma veteran who t…
Healthcare systems are pivoting towards preventing illness rather than curing it, with technology set to play a key role. To complete the transition however, new skills are likely to be equally important.
If the politicians and policymakers’ intent is to bend the healthcare cost curve, they must address growth in expenditures across all healthcare sectors, and not narrowly focus on prescription drug spending.
“We think that the fit is very strong between Takeda and Shire. We foresee minimal disruption on the R&D front.”
Yes, they did surgery on a grape.
More Americans approve of the Affordable Care Act than disapprove of it, 48% to 47%, a new Gallup Poll shows.
Male contraceptive science hasn’t exactly experienced an explosion of new products over the past century. But products like the NES/T gel are promising.
So how do we develop a system that results in effective treatment AND prevention AND continuous cost reduction? And does so in a way that makes the genetic modification of embryos and germ cells (sperm and eggs) less relevant?
Even when a company is doing well, female CEOs are more likely to be let go than male peers.
While gene editing is grabbing the headlines, technology to genetically select babies is already available and has been in use for years. Does it hold the same potential to transform humanity, and should it raise the same qualms?
